• Consensus Rating: Strong Sell
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 4
  • Breakdown:
  • 4 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.03
+0 (0.00%)

This chart shows the closing price for IDRSF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Idorsia Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for IDRSF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for IDRSF

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 4 analysts offering 12 month price targets for Idorsia in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $2.03.

This chart shows the closing price for IDRSF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Strong Sell

The current consensus among 4 investment analysts is to strong sell stock in Idorsia. This Strong Sell consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 4 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 4 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 4 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 4 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 4 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 4 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 4 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 4 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 4 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/6/2023CitigroupInitiated CoverageSell
6/22/2023Morgan StanleyInitiated CoverageUnderweight
4/26/2023Credit Suisse GroupDowngradeNeutral ➝ Underperform
4/25/2023Deutsche Bank AktiengesellschaftDowngradeHold ➝ Sell
1/18/2023Jefferies Financial GroupDowngradeBuy ➝ Hold
1/3/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ NeutralCHF 17 ➝ CHF 15
11/10/2022Credit Suisse GroupDowngradeOutperform ➝ Neutral
10/26/2022Credit Suisse GroupLower TargetOutperform ➝ OutperformCHF 25 ➝ CHF 21
10/21/2022Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold
7/22/2022Morgan StanleyLower TargetEqual Weight ➝ Equal WeightCHF 28 ➝ CHF 18
5/31/2022HC WainwrightBoost TargetCHF 35 ➝ CHF 36
2/14/2022HC WainwrightLower TargetBuy ➝ BuyCHF 41 ➝ CHF 35
10/27/2021JPMorgan Chase & Co.Reiterated RatingNeutral
10/12/2021Morgan StanleyReiterated RatingEqual Weight
10/12/2021HC WainwrightReiterated RatingBuy
9/16/2021Jefferies Financial GroupUpgradeHold ➝ Buy
7/28/2021JPMorgan Chase & Co.Reiterated RatingNeutral
7/19/2021BarclaysReiterated RatingOverweight
7/6/2021Credit Suisse GroupReiterated RatingOutperform
3/8/2021Credit Suisse GroupReiterated RatingOutperform
2/10/2021Morgan StanleyReiterated RatingEqual Weight
2/8/2021JPMorgan Chase & Co.Reiterated RatingNeutral
10/29/2020Morgan StanleyReiterated RatingEqual Weight
10/28/2020JPMorgan Chase & Co.Reiterated RatingNeutral
10/28/2020Deutsche Bank AktiengesellschaftReiterated RatingBuy
7/27/2020Morgan StanleyInitiated CoverageEqual Weight
7/8/2020JPMorgan Chase & Co.Initiated CoverageNeutral
6/15/2020Deutsche Bank AktiengesellschaftInitiated CoverageBuy
5/11/2020Credit Suisse GroupUpgradeNeutral ➝ Outperform
4/20/2020HC WainwrightReiterated RatingPositive ➝ Buy
4/16/2020CitigroupInitiated CoverageBuy
1/28/2020The Goldman Sachs GroupInitiated CoverageNeutral
12/16/2019HC WainwrightInitiated CoverageBuy
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.44 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/17/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/17/2023
  • 0 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/16/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/15/2024
  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/14/2024

Current Sentiment

  • 1 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

Idorsia logo
Idorsia Ltd, a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for unmet medical needs in Switzerland. The company has a clinical development pipeline that cover various therapeutic areas, including CNS, cardiovascular, and immunological disorders, as well as orphan diseases. Its products include PIVLAZ (clazosentan), available in 150 mg, is indicated for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage securing; and QUVIVIQ (daridorexant), available in 25 and 50 mg, for the treatment of adult patients with insomnia. Idorsia Ltd has a collaboration agreement with Janssen Biotech Inc. to jointly develop and commercialize aprocitentan and its derivative compounds or products; license agreement with Mochida Pharmaceutical for the supply, co-development, and comarketing of daridorexant; and Hoffman-La Roche Inc. to develop and market compounds in the field of cancer immunotherapy. It also has a collaboration with Neurocrine Biosciences, Inc. to develop and commercialize ACT-709478, which is in Phase II clinical trial for the treatment of epilepsy. The company was incorporated in 2017 and is headquartered in Allschwil, Switzerland.
Read More

Today's Range

Now: $2.03
Low: $2.03
High: $2.03

50 Day Range

MA: $2.01
Low: $1.50
High: $2.80

52 Week Range

Now: $2.03
Low: $1.40
High: $10.70

Volume

N/A

Average Volume

3,788 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Idorsia?

The following sell-side analysts have issued research reports on Idorsia in the last year: Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, and Morgan Stanley.
View the latest analyst ratings for IDRSF.

What is the current price target for Idorsia?

0 Wall Street analysts have set twelve-month price targets for Idorsia in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Idorsia in the next year.
View the latest price targets for IDRSF.

What is the current consensus analyst rating for Idorsia?

Idorsia currently has 4 sell ratings from Wall Street analysts. The stock has a consensus analyst rating of "Strong Sell."
View the latest ratings for IDRSF.

What other companies compete with Idorsia?

How do I contact Idorsia's investor relations team?

Idorsia's physical mailing address is Hegenheimermattweg 91, Allschwil, Basel-Landschaft (Basle. The company's listed phone number is (158) 844-0000. The official website for Idorsia is www.idorsia.com. Learn More about contacing Idorsia investor relations.